Drug therapy.
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002090:Butyrophenones / Q000009:adverse effects / Q000627:therapeutic use; D002188:Cannabis / Q000633:toxicity; D002749:Chlorprothixene / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000592:standards; D004359:Drug Therapy, Combination; D005116:Extrapyramidal Tracts; D006556:Heroin Dependence / Q000188:drug therapy; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008238:Lysergic Acid Diethylamide / Q000627:therapeutic use / Q000633:toxicity; D001523:Mental Disorders / Q000188:drug therapy*; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy; D009536:Niacinamide / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000627:therapeutic use; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013888:Thiothixene / Q000009:adverse effects / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D002090:Butyrophenones; D006993:Hypnotics and Sedatives; D009539:Nicotinic Acids; D010640:Phenothiazines; D010919:Placebos; D014149:Tranquilizing Agents; D009536:Niacinamide; D013888:Thiothixene; D008238:Lysergic Acid Diethylamide; D002749:Chlorprothixene